India’s deeptech funding record faces a test of scale: Speciale Invest
Deeptech is generally technology rooted in scientific research or advanced engineering, rather than a business built mainly around a familiar digital service. The article does not set a formal definition, but describes companies moving research and prototypes from the lab toward commercial products. That distinction matters because a promising invention is not yet a product customers can buy. The report’s examples include battery makers, semiconductor developers, space firms and life-sciences ventures. These companies may need to test technology, qualify products with customers, secure components and build production capacity. For instance, semiconductor developers still rely on overseas fabrication and packaging, while the first Indian fab is due in 2028. The article frames commercialisation as the central challenge: funding research alone is not enough. A startup also needs reliable customers, manufacturing support and growth capital at the right stage. Its findings show that Indian funding thins sharply after seed rounds, making it harder to carry technologies through testing and into production. Deeptech’s defining challenge is therefore not only invention, but turning invention into repeatable business.
What makes a company “deeptech” rather than a typical technology startup?
Deeptech is generally technology rooted in scientific research or advanced engineering, rather than a business built mainly around a familiar digital service. The article does not set a formal definition, but describes companies moving research and prototypes from the lab toward commercial products. That distinction matters because a promising invention is not yet a product customers can buy.
The report’s examples include battery makers, semiconductor developers, space firms and life-sciences ventures. These companies may need to test technology, qualify products with customers, secure components and build production capacity. For instance, semiconductor developers still rely on overseas fabrication and packaging, while the first Indian fab is due in 2028.
The article frames commercialisation as the central challenge: funding research alone is not enough. A startup also needs reliable customers, manufacturing support and growth capital at the right stage. Its findings show that Indian funding thins sharply after seed rounds, making it harder to carry technologies through testing and into production. Deeptech’s defining challenge is therefore not only invention, but turning invention into repeatable business.
How much did India’s deeptech startups raise in 2025, and how did their share of funding compare with their share of funding rounds?
India’s deeptech companies raised $914 million in 2025, spread across 257 funding rounds. That total was 34 times the 2016 level, showing a large rise in investment over the period. But the headline amount does not tell the whole story: India’s share of rounds was much larger than its share of the money invested.
The report puts India at 12.8% of global deeptech funding rounds in 2025, but just 1.6% of the capital. In other words, Indian companies secured a notable portion of deals, yet those deals represented a much smaller slice of total funding. The figures point to a difference in the scale of financing available.
That gap matters because deeptech firms may need substantial funding as they move from prototypes toward product qualification and production. The report also finds that Indian Series A and B rounds averaged $11.5 million from January to August 2026, compared with $55.5 million globally. The challenge is not simply attracting rounds; it is securing enough capital to scale.
What does the drop from seed funding to later-stage rounds reveal about Indian startups’ ability to grow?
The drop from seed funding to later rounds signals a bottleneck in the path from early promise to a growing company. For every 100 Indian seed rounds, there were 23 Series A or B rounds. Globally, the comparable figure was 105. The report also counts one late-stage or private-equity round per 100 Indian seed rounds, against 26 worldwide.
These ratios show that far fewer Indian companies receive later-stage funding relative to the number that start at seed stage. That matters because deeptech startups may need more capital after proving an idea: they must qualify products, win customers and prepare production. A prototype can work and still need considerable financing before it earns predictable revenue.
The figures point to a thinner funding pipeline as companies mature, not a measure of any one startup’s prospects. Speciale Invest calls for more domestic Series B and C investors and plant finance before pilots end. More follow-on funding could help companies address the costly steps between early research and commercial scale, though the article identifies funding as one part of a wider challenge that also includes customers and manufacturing.
Why can a successful pilot still fail to become a commercial order?
A pilot or customer trial tests whether a product works in a real setting, but success alone does not guarantee a commercial order. The article says turning a successful trial into an order remains difficult. A company may prove its technology without having an agreed path from the test to a buying decision.
The key mechanism is clarity about what the trial must prove and when the customer will decide whether to buy. Vishesh Rajaram of Speciale Invest says large companies and public-sector buyers can agree on these points upfront. Without that agreement, the startup may not know what evidence is sufficient or when a purchase decision will come.
A first order has consequences beyond revenue: it lets a startup plan production and commit to suppliers. Without one, the company may be less able to plan those next steps, especially when it needs to invest before commercial revenue is predictable. The report urges plant finance before pilots end, linking funding to the transition from trial to production. Clear purchase decisions can help make that transition more concrete.
How can large companies and public-sector buyers help a startup turn a trial into a first order?
Large companies and public-sector buyers can make the path from a trial to a sale clearer. The article identifies the transition from successful pilots to commercial orders as a persistent difficulty. An agreed process gives both the buyer and startup a shared understanding of what happens after testing.
Vishesh Rajaram, managing partner at Speciale Invest, says buyers should define in advance what a pilot must prove and when they will make a purchase decision. This gives the trial a clear test and a decision point, rather than leaving its outcome open-ended. If the buyer proceeds, the first order can provide a concrete commitment.
That commitment matters for production planning. Rajaram says a first order lets a startup plan production and commit to suppliers. This is especially relevant when a company must prepare to manufacture before commercial revenue is predictable. The report also urges plant finance before pilots end, suggesting that buyers’ clearer decisions and timely financing can support the move from trial toward production. It does not claim that every pilot will result in an order.
How do reliance on imported components and overseas factories make it harder for deeptech firms to scale production?
Deeptech firms that depend on imported components or overseas factories cannot rely entirely on domestic supply and production capacity. The report identifies battery makers’ reliance on imported cells and materials, and semiconductor developers’ dependence on overseas fabrication and packaging. These are manufacturing dependencies that can complicate a startup’s effort to scale production.
The article gives a contrast in batteries: Exide commissioned phase one of a 6 GWh Bengaluru cell plant in September. For semiconductors, the government approved Semicon 2.0 in July with Rs 1,27,500 crore to expand domestic capacity; the first fab is due in 2028. These developments aim to build more local manufacturing capability, but the article notes that reliance on overseas facilities remains.
For a startup trying to move from trial to production, dependence on external components and factories means its manufacturing path is not fully domestic. The article does not quantify the resulting delays or costs. It does identify these dependencies as a barrier to scaling, alongside limited growth capital and weak commercialisation pathways. Expanding local capacity could address part of that challenge, while firms still need customers and financing to grow.
Why do deeptech companies often need more patient, milestone-based financing than businesses that can grow without building physical products?
Deeptech companies often face costs before they have predictable commercial revenue. The article describes startups moving from research and prototypes through customer trials, product qualification and production. That path can require patient financing because important steps may come before a steady stream of sales. The article does not compare deeptech directly with businesses that can grow without physical products.
For example, a founder may need to qualify a product with a major customer or commission a production line before revenue is predictable. Vishnu Rajeev of Speciale Invest says funding should match these milestone costs. He also argues that project finance can be appropriate once customers make firm commitments, tying financing to a clearer commercial step.
The funding gap is significant: Indian Series A and B rounds averaged $11.5 million from January to August 2026, against $55.5 million globally. The report urges more domestic Series B and C investors and plant finance before pilots end. Patient, milestone-based capital can help bridge the period from trial to production, but reliable customers and workable manufacturing pathways remain important too.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web